Cytotheryx, a growing Rochester biotech firm working on treatments for liver disease, recently received $60 million in financing to advance its research and development. CEO Dr. John Swart announced ...

A study reveals advances in the understanding and treatment of liver fibrosis, a serious complication in the context of metabolic fatty liver disease, also known as MASLD (metabolic ...

The liver is accountable for metabolizing most medications and is therefore one of the primary tissues affected by adverse drug reactions. Most classes of medicine can cause drug-induced liver injury ...

An international team of researchers bioengineering human liver tissues uncovered previously unknown networks of genetic-molecular crosstalk that control the organ's developmental processes – greatly ...

Cardiovascular disease is a leading cause of mortality worldwide, affecting both men and women significantly. Liver diseases, including cirrhosis, ...

Myosteatosis is associated with poor outcomes in various liver diseases. However, standardized methods for assessing, defining, and diagnosing myosteatosis in the context of liver diseases remain ...

Familial Hypobetalipoproteinemia (FHBL), caused by variants in the apolipoprotein B (APOB) gene, is a rare autosomal ...